|
- DNA Damage Response | DDR Company | Artios Pharma
Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class best-in-class potential
- About Artios | Leadership | Scientific Advisors | Board
Artios is leading the DNA Damage Response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of pioneering DDR drug developers
- Pipeline - Artios Pharma
Artios plans to initiate a Phase 2 trial with ART6043 in combination with olaparib Artios is also exploring the potential of Polθ with DNA damaging agents such as chemotherapies, ionizing radiation and radioligand therapy as well as with immuno-oncology medicines
- News Events - Artios Pharma
Artios Pharma to Present at the 43rd Annual J P Morgan Healthcare Conference 19 December 2024 | Press release
- Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase . . .
Artios is pursuing a differentiated clinical development path with its lead product candidate, ART0380, which selectively targets a protein kinase called Ataxia telangiectasia and Rad3-related (ATR)
- Artios Pharma Announces Details of Presentations at the American . . .
CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical trial results from its ongoing Phase 1 2a study of ART0380 in combination with low
- DNA Damage Response | Clinical Trials - Artios Pharma
Targeting DNA Damage Response (DDR) pathways Artios leverages its unparalleled insights into the ensemble of DDR pathways within cells to go beyond synthetic lethality, unlocking new opportunities for patients with hard-to-treat cancers
- Press release Archives - Artios Pharma
Artios Pharma to Present at the 43rd Annual J P Morgan Healthcare Conference 19 December 2024 | Press release
|
|
|